Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „further“
Suchtreffer
Begriffe & Kennungen
Riximyo · 4.8 · 21 Re-treatment The percentage of patients reporting adverse reactions upon re-treatment with further courses
Eintrag öffnenRybelsus · 4.8 · Table 1 lists adverse reactions identified in phase 3 trials (further described in section 5.1) and post- mark
Eintrag öffnenRybelsus · 4.8 · Table 1 lists adverse reactions identified in phase 3 trials (further described in section 5.1) and post- mark
Eintrag öffnenSapropterin Dipharma · 4.8 · In a further clinical trial, approximately 30% of the 27 children aged below 4 years who received treatment wi
Eintrag öffnenSapropterin Dipharma · 4.8 · In a further clinical trial, approximately 30% of the 27 children aged below 4 years who received treatment wi
Eintrag öffnenSeebri Breezhaler · 4.8 · The safety profile is further characterised by other symptoms related to the anticholinergic effects, includin
Eintrag öffnenSiiltibcy · 4.8 · #: Please refer to “Description of selected adverse reactions” for further details.
Eintrag öffnenSlenyto · 4.8 · Furthermore, in ASD and neurogenetic children treated with 2-6 mg of the adult formulation under a Temporary R
Eintrag öffnenSpedra · 4.5 · Since the in vitro data identified potential avanafil interactions with CYPs 2C19, 2C8/9, 2D6 and 3A4, further
Eintrag öffnenSpedra · 4.5 · Since the in vitro data identified potential avanafil interactions with CYPs 2C19, 2C8/9, 2D6 and 3A4, further
Eintrag öffnenSpedra · 4.5 · Since the in vitro data identified potential avanafil interactions with CYPs 2C19, 2C8/9, 2D6 and 3A4, further
Eintrag öffnenSuboxone · 4.5 · • Furthermore, adequate analgesia may be difficult to achieve when administering a full opioid agonist in pati
Eintrag öffnenSuboxone · 4.5 · • Furthermore, adequate analgesia may be difficult to achieve when administering a full opioid agonist in pati
Eintrag öffnenTarceva · 4.8 · Second and Further Line Treatment
Eintrag öffnenTecentriq · 4.8 · Further details on serious adverse reactions are provided in section 4.4.
Eintrag öffnenTecentriq · 4.8 · Further details on serious adverse reactions are provided in section 4.4.
Eintrag öffnenTelmisartan Actavis · 4.8 · 1,2,3,4: for further descriptions, please see sub-section ”Description of selected adverse reactions”.
Eintrag öffnenTelmisartan Teva Pharma · 4.8 · : for further descriptions, please see sub-section ”Description of selected adverse reactions”. 1, 2, 3, 4
Eintrag öffnenTevagrastim · 4.8 · There is insufficient data to further evaluate filgrastim use in paediatric subjects.
Eintrag öffnenTolura · 4.8 · 1, 2, 3, 4: for further description, please see sub-section “Description of selected adverse reactions”
Eintrag öffnen